

Amendment to the Claims

This listing of claims will replace all prior versions of claims in the application:

Listing of Claims:

- 1-27. (Cancelled)
28. (New) An immunoconjugate comprising an antibody binding site of an immunoglobulin (Ig) chain linked to an interleukin (IL)-15.
29. (New) The immunoconjugate of claim 28, wherein the antibody binding site is capable of binding a specific surface antigen present on a preselected cell-type.
30. (New) The immunoconjugate of claim 29, wherein the preselected cell-type is a cancer cell or a virally-infected cell.
31. (New) The immunoconjugate of claim 30, wherein the cancer cell is in a solid tumour.
32. (New) The immunoconjugate of claim 28, wherein the antibody binding site is capable of binding an epithelial cell adhesion molecule (EpCAM).
33. (New) The immunoconjugate of claim 32, wherein the antibody binding site comprises a variable region derived from mouse KS-1/4 antibody.
34. (New) The immunoconjugate of claim 33, wherein the variable region is a humanized variable region.
35. (New) The immunoconjugate of claim 32, further comprising an immunoglobulin heavy chain constant region derived from an IgG1 heavy chain.

36. (New) The immunoconjugate of claim 32, further comprising an immunoglobulin heavy chain constant region derived from an IgG2 heavy chain.

37. (New) The immunoconjugate of claim 32, further comprising an immunoglobulin heavy chain constant region derived from an IgG3 heavy chain.

38. (New) The immunoconjugate of claim 32, further comprising an immunoglobulin heavy chain constant region derived from an IgG4 heavy chain.

39. (New) The immunoconjugate of claim 28, wherein the antibody binding site comprises a portion of an immunoglobulin (Ig) heavy chain.

40. (New) The immunoconjugate of claim 28, wherein the antibody binding site comprises an immunoglobulin variable region.

41. (New) The immunoconjugate of claim 40, further comprising an immunoglobulin constant region.

42. (New) The immunoconjugate of claim 41, wherein the immunoglobulin constant region comprises one or more of a CH1 domain, a CH2 domain, a CH3 domain or a CH4 domain.

43. (New) The immunoconjugate of claim 41, wherein the immunoglobulin constant region comprises a CH1 and a CH2 domain.

44. (New) The immunoconjugate of claim 40, further comprising an immunoglobulin hinge region.

45. (New) The immunoconjugate of claim 41, wherein the immunoglobulin constant region is derived from an immunoglobulin chain selected from the group consisting of an IgG, IgM and IgE chain.

46. (New) The immunoconjugate of claim 28, wherein the antibody binding site comprises a variable region of a heavy chain and a variable region of a light chain.

47. (New) The immunoconjugate of claim 28, further comprising a linker.

48. (New) An expression vector encoding the immunoconjugate of claim 28.

49. (New) A composition for administration to an animal comprising the immunoconjugate of claim 28 and a physiologically-acceptable carrier or vehicle.

50. (New) A method for inducing a cytotoxic immune response in an animal comprising the step of administering to a patient an immunoconjugate of claim 28.